Bristol Myers bags a long-awaited FDA OK for ozanimod — but the pandemic will keep it off the market
The FDA has come through with the long-awaited approval of ozanimod, the once top MS drug hopeful that was sidelined by the agency 2 years ago after Celgene was flagged for lame conduct in filing a drug application. But the global Covid-19 outbreak will keep it on the sidelines for awhile longer.
Now a new product for Bristol Myers Squibb in the wake of its $74 billion Celgene buyout, the drug will eventually be pitted against Novartis’ S1P1 rival Mayzent, which slipped ahead in the drug development race as Celgene stumbled and fell. J&J has its own rival in the field, ponesimod, which was recently filed for an OK of its own.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.